Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for breast density reduction in premenopausal women
NCT03629717Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2018
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of denosumab in breast cancer, sponsored by Washington University School of Medicine. Primary endpoints: Effect of denosumab on breast tissue gene pathway gene expression at Day 60, Effect of denosumab on pathways that may influence breast cancer development as measured by spatial transcriptomic analysis at Day 60 and 1 more. Started Jun 2018; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03629717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629717.